- Open Access
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
BMC Cancervolume 19, Article number: 366 (2019)
The original article was published in BMC Cancer 2017 17:332
Correction to: BMC Cancer
Following publication of the original article , it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:
Fig. 1 Swimlane plot of time to response, treatment duration, and duration of follow-up for efficacy-evaluable patients who achieved response in the mBCC cohort (a), those in the laBCC cohort with treatment duration > 20 months (b), and those in the laBCC cohort who were treated for < 20 months (c). laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma.
Sekulic A, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:332. https://doi.org/10.1186/s12885-017-3286-5.